Menopause Symptom (Kupperman Index) and HRT Management Calculator

Menopause Symptom (Kupperman Index) and HRT Management Calculator helps estimate Korea-related chronic treatment, biologic drug, dialysis, obesity medication, and long-term management assumptions in English.

Health cost scenario inputs

Enter Korea-related chronic care, eldercare, therapy, procedure, fertility, diagnostic, or medical tourism assumptions. Results are simplified planning estimates.

Treatment cost over period

₩720,000

Monitoring or support cost

₩600,000

Increase reserve

₩216,000

Planning window cost

₩1,536,000

60 months

This English page explains menopause self-assessment and hormone replacement therapy (HRT) management based on Korean and international guidance. The core tool is the Blatt-Kupperman Menopausal Index (KMI): 11 symptoms each rated 0-3 by severity and multiplied by a weight — hot flush/vasomotor (weight 4); paresthesia, insomnia, and nervousness (weight 2 each); and melancholia, vertigo, weakness/fatigue, arthralgia/myalgia, headache, palpitations, and formication (weight 1 each) — for a maximum of 51. The widely used interpretation is: under 15 minimal, 15-20 mild, 21-35 moderate, and over 35 severe (a screening tool, not a diagnosis). It then estimates the menopause stage (premenopause, perimenopause, postmenopause after 12+ months of amenorrhea, or surgical menopause; the average natural menopause age in Korea is about 49.7). HRT suitability screens for absolute contraindications (breast cancer, endometrial cancer, unexplained vaginal bleeding, venous thromboembolism, active liver disease, coronary heart disease, prior stroke/TIA, pregnancy) and the "window of opportunity" — starting before age 60 and within 10 years of menopause has the most favorable benefit/risk profile (NAMS 2022). Women with a uterus need combined estrogen-progestogen therapy (EPT) to protect the endometrium, while women after hysterectomy can use estrogen alone (ET); tibolone (Livial) is a single agent. Menopausal HRT is covered by Korean National Health Insurance and is low-cost; monthly drug cost and periodic monitoring (mammography, bone-density DEXA at T-score ≤ -2.5, endometrial ultrasound, blood tests) are rough reference estimates. It is educational planning guidance based on 2026 Korean rules, not medical advice, a diagnosis, a prescription, or an insurer/benefit decision — decisions about starting HRT, formulation, dose, and duration must be made with a gynecologist.

Related calculators

What is the menopause (Kupperman Index) and HRT management calculator?

This calculator lets women in perimenopause or menopause self-assess their symptom severity with the Blatt-Kupperman Menopausal Index (KMI), then check their menopause stage, hormone replacement therapy (HRT) suitability, and estimated management cost — all in one place.
Beyond simply asking “am I in menopause?”, it summarizes which symptoms are most severe, whether HRT can be considered, and which regimen fits, on an evidence basis.

Menopause (the peri- and post-menopausal period) is when ovarian function declines and the female hormone estrogen falls sharply.
The average natural menopause age in Korea is about 49.7 years, and menopause is defined as 12 or more months of amenorrhea after the final period.

Korea-based estimate. This tool combines the international Kupperman Menopausal Index with Korea-specific HRT context (National Health Insurance coverage of menopausal HRT, bone-density DEXA reimbursement at T-score ≤ -2.5, and 2026 rules). It is an educational planning aid, not medical advice, and does not replace diagnosis, a prescription, treatment decisions, or an insurer/benefit decision. Decisions about starting HRT, the formulation, dose, and duration must be made with a gynecologist.

The Kupperman Menopausal Index (KMI)

The Kupperman Index, devised by Blatt and Kupperman in 1953, is still widely used in clinics and for self-assessment.
Each of 11 representative symptoms is rated none (0), mild (1), moderate (2), or severe (3), then multiplied by a symptom-specific weight and summed.

The 11 symptoms and weights

  • • Hot flush / sweating (vasomotor): weight 4 — the hallmark vasomotor symptom and the largest single contributor.
  • • Paresthesia (tingling/numbness): weight 2
  • • Insomnia: weight 2
  • • Nervousness / irritability: weight 2
  • • Melancholia, vertigo, weakness/fatigue, arthralgia/myalgia, headache, palpitations, formication: weight 1 each

The weights sum to 17, so the maximum score is 17 × 3 = 51.
The total is the sum of “severity (0-3) × weight” across all 11 symptoms.

Interpretation thresholds

  • • 0-14: minimal — no clear menopausal syndrome; lifestyle management is often enough.
  • • 15-20: mild — management is needed; lifestyle measures and consultation are recommended.
  • • 21-35: moderate — affects quality of life; a treatment consultation including HRT is recommended.
  • • 36-51: severe — see a specialist; if there are no contraindications, active treatment can be considered.

The Kupperman Index is a symptom screening tool, not a tool that confirms menopause or a disease diagnosis.
Thyroid disease, anemia, and depression can cause similar symptoms, so a high score should be evaluated by a specialist to identify the cause.

Understanding the menopause stage

Menopause is divided into stages around the final period, and symptoms and management strategy differ by stage.
This calculator infers the stage from your menstrual status and months since the last period.

  • • Premenopause: regular menstruation continues. Symptoms after age 45 may be an early sign of the transition.
  • • Perimenopause (irregular cycles): cycles become erratic; vasomotor symptoms such as hot flushes and sleep disturbance are most common.
  • • Postmenopause (12+ months of amenorrhea): persistent estrogen deficiency makes osteoporosis and cardiovascular risk management important.
  • • Surgical menopause: menopause from removal of the uterus/ovaries; ovarian removal drops hormones abruptly, so symptoms can be more acute.

Assessing HRT suitability

HRT (menopausal hormone therapy) replaces the declining female hormones to relieve hot flushes, sleep disturbance, and vaginal dryness, and to prevent bone loss.
It is not suitable for everyone, so contraindications, timing, and the presence of a uterus must be considered.

Absolute contraindications (systemic HRT not suitable)

  • • Breast cancer (history or current) / endometrial cancer history
  • • Unexplained vaginal bleeding
  • • Venous thromboembolism (deep vein thrombosis / pulmonary embolism) history
  • • Active liver disease
  • • Coronary (ischemic) heart disease / prior stroke or TIA
  • • Pregnancy

If any apply, systemic HRT is not suitable; discuss non-hormonal options (SSRIs/SNRIs, gabapentin, low-dose local vaginal therapy) and lifestyle management with a specialist.

The window of opportunity

According to the North American Menopause Society (NAMS 2022) position statement, the benefit/risk profile of HRT is most favorable when started before age 60 and within 10 years of menopause.
Starting for the first time after age 60 or more than 10 years past menopause can carry relatively higher cardiovascular and clot risk, so individual risk assessment matters even more.

Relative cautions (hypertension, migraine with aura, gallstones, family history of breast cancer, uterine fibroids/endometriosis, uncontrolled diabetes) call for careful judgment.

Regimen by presence of a uterus

  • • Uterus present → combined estrogen-progestogen therapy (EPT): estrogen alone raises the risk of endometrial hyperplasia and cancer, so a progestogen must be combined to protect the endometrium.
  • • After hysterectomy → estrogen-only therapy (ET): estrogen can be used without a progestogen.
  • • Tibolone (Livial): a single agent with estrogenic, progestogenic, and androgenic activity, so no separate progestogen is needed.

Formulations and representative drugs

HRT comes in many forms — oral tablets, transdermal gel, patches, and local vaginal suppositories.
Convenience, clot risk, and cost differ slightly by formulation.

  • • Oral combined (Angeliq, Femoston, Klimen): the standard for women with a uterus. Estrogen and progestogen in one daily tablet.
  • • Tibolone (Livial): a single agent favorable for low libido, bone density, and muscle preservation.
  • • Transdermal gel/patch (Estrogel, Estrava, Climara): bypasses first-pass liver metabolism, so clot risk is relatively lower — often preferred in older or higher-clot-risk women. A progestogen is combined if a uterus is present.
  • • Local vaginal suppository (Ovestin): focused on local symptoms such as vaginal dryness/atrophy, with little systemic absorption.
  • • Progestogen (Duphaston, micronized progesterone): combined by women with a uterus who use estrogen-only formulations (gel/patch).

Cost and National Health Insurance coverage

HRT for the purpose of treating menopausal symptoms is covered by Korean National Health Insurance, and the drugs themselves are relatively inexpensive.
It can be prescribed under coverage based on symptoms, without hormone-level testing.

Reference cost (covered basis, estimates)

  • • Monthly drug cost: roughly KRW 8,000-15,000 oral combined, 10,000-18,000 tibolone, 12,000-25,000 transdermal gel, 15,000-30,000 patch, 5,000-12,000 local vaginal.
  • • Annual monitoring: mammography (free under the national screening program for those 40+ every 2 years), bone-density DEXA (coverage at T-score ≤ -2.5), endometrial ultrasound, and lipid/liver blood tests.
  • • Sequential progestogen: adds to the monthly drug cost when a woman with a uterus uses an estrogen-only formulation.

The calculator’s cost is a reference estimate range, not an exact bill.
Actual drug cost varies by product, days dispensed, provider, and coverage, so confirm exact amounts with HIRA, the pharmacy, or the hospital.

How to use this calculator

Step 1: Basic information

Enter your age, menopause status (premenopause, perimenopause, postmenopause, surgical), months since the last period, and whether you have a uterus.

Step 2: Kupperman symptom rating

Rate the 11 symptoms from none to severe; the weights are applied to compute your total and grade automatically.

Step 3: Contraindications and cautions

Check the absolute contraindications and relative cautions to determine HRT suitability.

Step 4: Formulation and cost

Pick your formulation and monitoring level to see the estimated management cost, recommended regimen, and overall guidance.

Frequently asked questions (FAQ)

Q. At what Kupperman score is treatment needed?

A. Generally, 15 or more indicates that management is needed.
21-35 is moderate and warrants a treatment consultation including HRT, and 36+ is severe and needs a specialist.

Q. Doesn’t HRT increase breast cancer risk?

A. Long-term combined estrogen-progestogen therapy can raise breast cancer risk slightly, but the absolute risk of short-term use is very low.
Estrogen-only therapy has even been reported to lower risk, so the individual risk/benefit must be assessed with a specialist.

Q. Do I still need a progestogen if I have no uterus?

A. No.
The progestogen is to protect the endometrium, so after a hysterectomy estrogen-only therapy is used.

Q. When is the best time to start HRT?

A. Before age 60 and within 10 years of menopause is the so-called window of opportunity.
Starting in this period tends to have benefits exceeding risks, and the later you start, the more important individual risk assessment becomes.

Q. What tests are needed during HRT?

A. Check mammography and blood pressure regularly, and add bone density (DEXA) and endometrial ultrasound as needed.
Any abnormal vaginal bleeding should be evaluated promptly.

Important notes

  • Reference tool: this calculator is an educational aid based on public medical information and does not replace medical advice, diagnosis, or prescription.
  • Screening tool: the Kupperman Index is a symptom screening tool, not a diagnostic one. A specialist visit is needed to rule out other causes.
  • Individual judgment: the start, formulation, dose, and duration of HRT must be decided with a gynecologist for your situation.
  • Costs vary: drug and test costs are covered-basis estimates and actual amounts may differ.

Check your menopause index now

Just select your symptoms to see the Kupperman score, menopause stage, HRT suitability, and estimated management cost at once.

Use the result as reference material for a specialist consultation.